[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

AR089753A1 - Derivados de amida heterociclicos como antagonistas del receptor p2x7 - Google Patents

Derivados de amida heterociclicos como antagonistas del receptor p2x7

Info

Publication number
AR089753A1
AR089753A1 ARP130100155A ARP130100155A AR089753A1 AR 089753 A1 AR089753 A1 AR 089753A1 AR P130100155 A ARP130100155 A AR P130100155A AR P130100155 A ARP130100155 A AR P130100155A AR 089753 A1 AR089753 A1 AR 089753A1
Authority
AR
Argentina
Prior art keywords
substituted
alkyl
hydroxy
halogen
mono
Prior art date
Application number
ARP130100155A
Other languages
English (en)
Original Assignee
Actelion Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Actelion Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd
Publication of AR089753A1 publication Critical patent/AR089753A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Reivindicación 1: Un compuesto de la fórmula (1), donde n representa 1 ó 2; X representa -N- o -N(O)-; R¹ representa hidrógeno o halógeno; R² representa hidrógeno o metilo; y R³ representa: aril-alquilo C₁₋₃, el cual está en la parte alquilo opcionalmente mono-sustituido con hidroxi o heterociclilo; y el cual está en la parte arilo mono-, di- o tri-sustituido, donde los sustituyentes se seleccionan -de manera independiente- del grupo que consiste de alquilo C₁₋₄, alquenilo C₂₋₄, cicloalquilo C₃₋₆, alcoxi C₁₋₄, hidroxi-alquilo C₁₋₃, hidroxi-alcoxi C₂₋₃, hidroxi-alcoxi C₂₋₃-alquilo C₁₋₂, alcoxi C₁₋₂-alquilo C₁₋₂, fluoroalquilo C₁₋₃, fluoroalcoxi C₁₋₃, ciano, halógeno y fenoxi; o heteroaril-alquilo C₁₋₃, el cual está en la parte alquilo mono-sustituido con heterociclilo; y el cual está en la parte heteroarilo mono-, di- o tri-sustituido, donde los sustituyentes se seleccionan -de manera independiente- del grupo que consiste de alquilo C₁₋₄, cicloalquilo C₃₋₆, alcoxi C₁₋₄, fluoroalquilo C₁₋₃ y halógeno; o cicloalquilo C₃₋₇, el cual está mono-sustituido con -C(O)NH₂ o un fenilo opcionalmente mono-, di- o tri-sustituido, donde los sustituyentes se seleccionan de halógeno; o cicloalquilo C₅₋₇, el cual está opcionalmente mono-sustituido con hidroxi u oxo; y el cual está hibridado con un fenilo opcionalmente mono-, di- o tri-sustituido, donde los sustituyentes se seleccionan de halógeno; o cicloalquil C₃₋₇-alquilo C₁₋₃, el cual está en la parte alquilo opcionalmente mono-sustituido con hidroxi; y el cual está en la parte cicloalquilo opcionalmente di-sustituido con halógeno y opcionalmente mono-sustituido con hidroxi, arilo o heteroarilo, donde los grupos arilo o heteroarilo están opcionalmente mono-, di- o tri-sustituidos con halógeno; o una sal de dicho compuesto.
ARP130100155A 2012-01-20 2013-01-18 Derivados de amida heterociclicos como antagonistas del receptor p2x7 AR089753A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IB2012050282 2012-01-20

Publications (1)

Publication Number Publication Date
AR089753A1 true AR089753A1 (es) 2014-09-17

Family

ID=47757670

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP130100155A AR089753A1 (es) 2012-01-20 2013-01-18 Derivados de amida heterociclicos como antagonistas del receptor p2x7

Country Status (23)

Country Link
US (1) US9409917B2 (es)
EP (1) EP2804865B1 (es)
JP (1) JP6111268B2 (es)
KR (1) KR102033190B1 (es)
CN (1) CN104066737B (es)
AR (1) AR089753A1 (es)
AU (1) AU2013210682B2 (es)
BR (1) BR112014017735B1 (es)
CA (1) CA2863228C (es)
CL (1) CL2014001772A1 (es)
EA (1) EA024204B1 (es)
ES (1) ES2563189T3 (es)
HK (1) HK1203932A1 (es)
IL (1) IL233662A0 (es)
MA (1) MA35893B1 (es)
MX (1) MX336247B (es)
NZ (1) NZ628910A (es)
PH (1) PH12014501415A1 (es)
PL (1) PL2804865T3 (es)
SG (1) SG11201403933UA (es)
TW (1) TWI576347B (es)
WO (1) WO2013108227A1 (es)
ZA (1) ZA201406085B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR087274A1 (es) 2011-07-22 2014-03-12 Actelion Pharmaceuticals Ltd Derivados de amidas heterociclicas como antagonistas de receptores p2x7
KR102232742B1 (ko) 2012-12-12 2021-03-26 이도르시아 파마슈티컬스 리미티드 Ｐ２ｘ７ 수용체 길항제로서의 인돌 카르복사미드 유도체
KR102232744B1 (ko) 2012-12-18 2021-03-26 이도르시아 파마슈티컬스 리미티드 Ｐ２ｘ７ 수용체 길항제로서의 인돌 카르복사미드 유도체
ES2616114T3 (es) 2013-01-22 2017-06-09 Actelion Pharmaceuticals Ltd. Derivados de amida heterocíclica como antagonistas del receptor P2X7
EP2956457B1 (en) 2013-01-22 2016-11-23 Actelion Pharmaceuticals Ltd Heterocyclic amide derivatives as p2x7 receptor antagonists
RU2706239C2 (ru) * 2014-03-26 2019-11-15 Дзе Чилдрен'З Медикал Сентер Корпорейшн Целастрол и его производные для лечения ожирения
HRP20231682T1 (hr) 2017-03-13 2024-03-29 Raqualia Pharma Inc. Derivati tetrahidrokinolina kao antagonisti p2x7 receptora
SG11202006296YA (en) 2018-01-19 2020-08-28 Cytokinetics Inc Dihydrobenzofuran and inden analogs as cardiac sarcomere inhibitors
WO2020005887A1 (en) 2018-06-26 2020-01-02 Cytokinetics, Inc. Cardiac sarcomere inhibitors
EP3814343B1 (en) 2018-06-26 2023-01-11 Cytokinetics, Inc. Cardiac sarcomere inhibitors
JP2024508526A (ja) 2021-03-04 2024-02-27 サイトキネティックス， インコーポレイテッド 心筋サルコメア阻害剤

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ514477A (en) 1999-04-09 2003-04-29 Astrazeneca Ab Adamantane derivatives
SE9904505D0 (sv) 1999-12-09 1999-12-09 Astra Pharma Prod Novel compounds
TWI258462B (en) 1999-12-17 2006-07-21 Astrazeneca Ab Adamantane derivative compounds, process for preparing the same and pharmaceutical composition comprising the same
GB0013737D0 (en) 2000-06-07 2000-07-26 Astrazeneca Ab Novel compounds
WO2003042190A1 (en) 2001-11-12 2003-05-22 Pfizer Products Inc. N-alkyl-adamantyl derivatives as p2x7-receptor antagonists
PA8557501A1 (es) 2001-11-12 2003-06-30 Pfizer Prod Inc Benzamida, heteroarilamida y amidas inversas
SE0103836D0 (sv) 2001-11-16 2001-11-16 Astrazeneca Ab Novel compounds
SE0200920D0 (sv) 2002-03-25 2002-03-25 Astrazeneca Ab Novel compounds
PA8591801A1 (es) 2002-12-31 2004-07-26 Pfizer Prod Inc Inhibidores benzamidicos del receptor p2x7.
MXPA05007130A (es) 2002-12-31 2005-08-26 Pfizer Prod Inc Inhibidores benzamida del receptor p2x7.
SE0300480D0 (sv) 2003-02-21 2003-02-21 Astrazeneca Ab Novel compounds
ATE355273T1 (de) 2003-05-12 2006-03-15 Pfizer Prod Inc Benzamidinhibitoren des p2x7-rezeptors
GB0312609D0 (en) 2003-06-02 2003-07-09 Astrazeneca Ab Novel compounds
SE0302139D0 (sv) 2003-07-28 2003-07-28 Astrazeneca Ab Novel compounds
US20070073517A1 (en) * 2003-10-30 2007-03-29 Koninklijke Philips Electronics N.V. Method of predicting input
EP1747206A1 (en) 2004-04-29 2007-01-31 Abbott Laboratories Amino-tetrazoles analogues and methods of use
SA05260265A (ar) 2004-08-30 2005-12-03 استرازينيكا ايه بي مركبات جديدة
SE0402925D0 (sv) 2004-11-30 2004-11-30 Astrazeneca Ab Novel Compounds
JP2008528580A (ja) 2005-01-27 2008-07-31 アストラゼネカ・アクチエボラーグ Ｐ２ｘ７受容体の阻害剤である新規二環式芳香族化合物
DE602006004964D1 (de) 2005-02-10 2009-03-12 Bristol Myers Squibb Co Dihydrochinazolinone als 5ht-modulatoren
US7297700B2 (en) 2005-03-24 2007-11-20 Renovis, Inc. Bicycloheteroaryl compounds as P2X7 modulators and uses thereof
WO2007055374A1 (ja) * 2005-11-14 2007-05-18 Mitsubishi Tanabe Pharma Corporation 骨粗鬆症治療剤
WO2007109172A2 (en) 2006-03-16 2007-09-27 Renovis, Inc. Bicycloheteroaryl compounds as p2x7 modulators and uses thereof
US20100184802A1 (en) 2006-03-16 2010-07-22 Kelly Michael G Bicycloheteroaryl Compounds as P2X7 Modulators and Uses Thereof
CA2645652A1 (en) 2006-03-16 2007-09-27 Renovis, Inc. Bicycloheteroaryl compounds as p2x7 modulators and uses thereof
US20100298285A1 (en) 2006-03-16 2010-11-25 Kelly Michael G Biclycloheteroaryl Compounds as P2x7 Modulators and Uses Thereof
TWI464148B (zh) 2006-03-16 2014-12-11 Evotec Us Inc 作為ｐ２ｘ7調節劑之雙環雜芳基化合物與其用途
ES2596532T3 (es) 2006-03-16 2017-01-10 Second Genome, Inc. Compuestos de bicicloheteroarilo como moduladores de P2X7 y usos de los mismos
GB0611154D0 (en) 2006-06-06 2006-07-19 Glaxo Group Ltd Novel receptor antagonists and their methods of use
WO2007141267A1 (en) 2006-06-06 2007-12-13 Glaxo Group Limited N- (phenylmethyl) -2- (1h-pyraz0l-4-yl) acetamide derivatives as p2x7 antagonists for the treatment of pain, inflammation and neurodegeneration
PL2049478T3 (pl) 2006-07-06 2012-09-28 Glaxo Group Ltd Podstawione N-fenylometylo 5-okso-prolino-2-amidy jako antagoniści receptora P2X7 oraz sposoby ich zastosowania
MX2009005478A (es) 2006-11-27 2009-08-12 Lundbeck & Co As H Derivados de heteroarilamida.
TW200838516A (en) 2007-01-31 2008-10-01 Merck & Co Inc Substituted pyrano[2,3-B]pyridine derivatives as cannabinoid-1 receptor modulators
EP2124562B1 (en) 2007-03-09 2016-04-20 Second Genome, Inc. Bicycloheteroaryl compounds as p2x7 modulators and uses thereof
WO2008114002A1 (en) 2007-03-22 2008-09-25 Astrazeneca Ab Quinoline derivatives for the treatment of inflammatory diseases
GB0705882D0 (en) 2007-03-27 2007-05-02 Glaxo Group Ltd Novel compounds
EP2139858A1 (en) 2007-03-28 2010-01-06 Glaxo Group Limited Piperidinone carboxamide derivatives as p2x7 modulators
JP2010522710A (ja) 2007-03-29 2010-07-08 グラクソ グループ リミテッド Ｐ２ｘ７調節因子としてのオキサゾリジンおよびモルホリンカルボキサミド誘導体
BRPI0809930A2 (pt) 2007-04-03 2014-10-07 Glaxo Group Ltd Derivados de carboxamida imidazolidina como moduladores de p2x7
MX2009010523A (es) 2007-04-10 2009-12-15 Lundbeck & Co As H Análogos de amidas heteroarílicas como antagonistas de p2x7.
US20100056595A1 (en) 2007-04-11 2010-03-04 Glaxo Group Limited Pyrazole Derivatives as P2X7 Modulators
ATE502017T1 (de) 2007-05-10 2011-04-15 Glaxo Group Ltd Pyrazolderivate als p2x7-modulatoren
CN101711245B (zh) 2007-07-19 2015-03-25 H.隆德贝克有限公司 5元杂环酰胺及相关的化合物
BRPI0812594A2 (pt) * 2007-08-10 2015-06-23 Lundbeck & Co As H Composto ou sal ou hidrato do mesmo, composição farmacêutica, métodos para modulação da atividade de um receptor p2x7, para tratamento de uma condição responsiva á modulação do receptor p2x7 em um paciente, para inibição de morte de células gangliônicas retinais em um paciente, para determinação da presença ou ausência de receptor p2x7 em uma amostra, preparação farmacêutica acondicionada, e, uso de um composto ou sal ou hidrato do mesmo.
PE20091036A1 (es) 2007-11-30 2009-08-15 Astrazeneca Ab Derivado de quinolina como antagonista del receptor p2x7
GB0724258D0 (en) 2007-12-12 2008-01-30 Glaxo Group Ltd Novel combinations
WO2009074518A1 (en) 2007-12-12 2009-06-18 Glaxo Group Limited Combinations of prolinamide p2x7 modulators with further therapeutic agents
GB0724625D0 (en) 2007-12-18 2008-01-30 Glaxo Group Ltd Novel compounds
CN101945655A (zh) 2007-12-18 2011-01-12 葛兰素集团有限公司 作为p2x7调节剂的5-氧代-3-吡咯烷甲酰胺衍生物
WO2009108551A2 (en) 2008-02-25 2009-09-03 H. Lundbeck A/S Heteroaryl amide analogues
EA022505B1 (ru) 2008-03-25 2016-01-29 Эффектис Фармасьютиклз Аг Новые p2x7r антагонисты и их применение
KR101598397B1 (ko) 2008-04-22 2016-02-29 얀센 파마슈티카 엔.브이. 퀴놀린 또는 이소퀴놀린 치환된 피2엑스7 안타고니스트
DK2243772T3 (da) 2009-04-14 2012-02-13 Affectis Pharmaceuticals Ag Hidtil ukendte P2X7R-antagonister og deres anvendelse
GB0919594D0 (en) 2009-11-09 2009-12-23 Glaxo Group Ltd Compounds
US20120157494A1 (en) 2010-12-16 2012-06-21 Harris Iii Ralph New Isoindolyl compounds
KR20140009374A (ko) 2011-02-22 2014-01-22 액테리온 파마슈티칼 리미티드 Ｐ2ｘ7 수용체 안타고니스트로서의 벤즈아미드 유도체
WO2012163792A1 (en) 2011-05-27 2012-12-06 Affectis Pharmaceuticals Ag Novel p2x7r antagonists and their use
AR087274A1 (es) * 2011-07-22 2014-03-12 Actelion Pharmaceuticals Ltd Derivados de amidas heterociclicas como antagonistas de receptores p2x7
KR102232742B1 (ko) 2012-12-12 2021-03-26 이도르시아 파마슈티컬스 리미티드 Ｐ２ｘ７ 수용체 길항제로서의 인돌 카르복사미드 유도체
KR102232744B1 (ko) 2012-12-18 2021-03-26 이도르시아 파마슈티컬스 리미티드 Ｐ２ｘ７ 수용체 길항제로서의 인돌 카르복사미드 유도체
EP2956457B1 (en) 2013-01-22 2016-11-23 Actelion Pharmaceuticals Ltd Heterocyclic amide derivatives as p2x7 receptor antagonists
ES2616114T3 (es) 2013-01-22 2017-06-09 Actelion Pharmaceuticals Ltd. Derivados de amida heterocíclica como antagonistas del receptor P2X7

Also Published As

Publication number Publication date
ZA201406085B (en) 2016-05-25
CL2014001772A1 (es) 2014-10-17
HK1203932A1 (en) 2015-11-06
JP2015504086A (ja) 2015-02-05
CA2863228A1 (en) 2013-07-25
AU2013210682B2 (en) 2017-05-25
PH12014501415A1 (en) 2014-09-22
KR20140112567A (ko) 2014-09-23
IL233662A0 (en) 2014-08-31
MX336247B (es) 2016-01-13
KR102033190B1 (ko) 2019-10-16
WO2013108227A1 (en) 2013-07-25
JP6111268B2 (ja) 2017-04-05
TWI576347B (zh) 2017-04-01
MA35893B1 (fr) 2014-12-01
AU2013210682A1 (en) 2014-09-11
MX2014008736A (es) 2014-08-29
CN104066737B (zh) 2016-06-08
EA024204B1 (ru) 2016-08-31
CN104066737A (zh) 2014-09-24
BR112014017735A8 (pt) 2017-12-26
US20150025075A1 (en) 2015-01-22
EP2804865B1 (en) 2015-12-23
BR112014017735A2 (pt) 2017-06-27
CA2863228C (en) 2020-07-21
PL2804865T3 (pl) 2016-06-30
BR112014017735B1 (pt) 2022-06-28
NZ628910A (en) 2016-02-26
EA201400822A1 (ru) 2014-12-30
SG11201403933UA (en) 2014-08-28
US9409917B2 (en) 2016-08-09
EP2804865A1 (en) 2014-11-26
ES2563189T3 (es) 2016-03-11
TW201333013A (zh) 2013-08-16

Similar Documents

Publication Publication Date Title
AR089753A1 (es) Derivados de amida heterociclicos como antagonistas del receptor p2x7
AR093921A1 (es) Derivados de indol carboxamida como antagonistas del receptor p2x7
AR099677A1 (es) Compuesto heterocíclico fusionado y su uso para el control de plagas
AR100645A1 (es) Derivados de pirazolo-pirimidina
AR095311A1 (es) 3-pirimidin-4-il-oxazolidin-2-onas como inhibidores de idh mutante
AR097866A1 (es) Derivados de 4-azaindol
RU2017123807A (ru) Пиколинамиды с фунгицидной активностью
AR080057A1 (es) Piridinas disustituidas como anticancerigenos
AR093818A1 (es) Compuesto de 1-(bencil sustituido)piperazina sustituida
AR101558A1 (es) Difluoropirrolidinas como moduladores del receptor de orexina
AR090967A1 (es) Picolinamidas macrociclicas como fungicidas
AR094712A1 (es) Modificador de sabor dulce
AR101815A1 (es) Compuestos y composiciones como inhibidores de quinasa
AR097253A1 (es) Derivado de pirazolilpirazol sustituido y el uso del mismo como herbicida
AR099646A1 (es) Fotoestabilizantes de aminas impedidas
AR091519A1 (es) Inhibidores pirrolopirazona de tanquirasa
AR102217A1 (es) Derivados de benzotiofenilo sustituidos como agonistas de gpr40 para el tratamiento de la diabetes tipo ii
AR106486A1 (es) Antagonistas de receptores de cgrp
AR105549A1 (es) Compuestos de 1-alquil-6-oxo-1,6-dihidropiridin-3-ilo y usos de los mismos
AR101255A1 (es) Derivados de isoindolinona
AR097932A1 (es) Antagonista del receptor de somatostatina del subtipo 5 (sstr5)
AR097252A1 (es) Derivado de pirazolilpirazol sustituido y el uso del mismo como herbicida
AR097245A1 (es) Derivado de pirazolilpirazol sustituido y su empleo como herbicida
AR093128A1 (es) Inhibidores de la syk
AR101222A1 (es) Derivados de piridona

Legal Events

Date Code Title Description
FB Suspension of granting procedure